{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:07:21Z","timestamp":1777928841599,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,6,11]],"date-time":"2009-06-11T00:00:00Z","timestamp":1244678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,6,11]],"date-time":"2009-06-11T00:00:00Z","timestamp":1244678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology"],"abstract":"<jats:p>17 patients with diffuse non-Hodgkin\u2019s lymphoma with unfavorable histologies were treated with cyclophosphamide, hydroxyldaunorubicin (doxorubicin), vincristine (Oncovin), prednisone and bleomycin (CHOP-Bleo). Of the 16 patients entering a complete remission, 8 remain in remission at 46 + , 50+, 51 +, 61 +, 61 +, 61 + and 63 + months. There were 2 treatment deaths in elderly patients, both in remission. 2 of the early relapses ( &lt; 12 months) were later characterized as lymphoblastic lymphoma upon review of the original pathology. All 3 patients with late relapses (32, 37, and 44 months), were able to be successfully retreated. The 2 patients with lymphoblastic lymphoma developed central nervous system disease despite prophylactic intrathecal methotrexate; but central nervous system disease has not developed in the 4 other patients with initial bone marrow involvement who received prophylactic intrathecal therapy.<\/jats:p>","DOI":"10.1159\/000225722","type":"journal-article","created":{"date-parts":[[2009,6,12]],"date-time":"2009-06-12T10:29:57Z","timestamp":1244802597000},"page":"186-191","source":"Crossref","is-referenced-by-count":2,"title":["Long-Term Results of Patients with Advanced Diffuse, Non-Hodgkin\u2019s Lymphoma Treated with Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Bleomycin (CHOP-Bleo)"],"prefix":"10.1159","author":[{"given":"Delvyn C.","family":"Case, Jr.","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,6,11]]},"container-title":["Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/225722","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000225722","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:22:30Z","timestamp":1777677750000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000225722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000225722","archive":["Portico"],"relation":{},"ISSN":["0030-2414","1423-0232"],"issn-type":[{"value":"0030-2414","type":"print"},{"value":"1423-0232","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,11]]}}}